Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | Chief Scientific Officer | October 12, 2016 | October 14, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harvard Apparatus Regenerative Technology, Inc.
Report date October 12, 2016 · Filed October 14, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2016-10-12 transaction · row 1
1 source rowRow 1 · 2016-10-12 · Purchase · Acquired 10,000 · Balance 10,000 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.91, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.91, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2016 Filed Oct 14, 2016 12:00 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | PurchaseCommon Stock | 10,000 | $0.91 | $9,100.00 |
DisclosureSEC source: 0001144204-16-128079 · v450526_form4.xml · nonDerivative · entry 1 DerSimonian Harout · CIK 0001680625 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.91, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.